RxDoctor Payments Data

Cory Thomas, DO

Family Medicine · Cambridge City, INNPI 1609373281

Payments from drug & device makers

$1,989in general payments, 2019–2025

Across 125 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$610
  • Novo Nordisk$284
  • AstraZeneca$273
  • Amgen$231
  • Exact Sciences$154
  • Mylan Specialty L.p.$66
  • plus $371 from 14 others

What the payments were for

  • Food & beverage$1,94498%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,989 in reported general payments places this provider in the 70th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$3,002
Medicare patients
17
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$97,671
TrulicityDulaglutide49$75,342
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$70,777
JardianceEmpagliflozin58$57,648
FarxigaDapagliflozin Propanediol53$52,595
EliquisApixaban50$50,308
MounjaroTirzepatide37$50,078
JanuviaSitagliptin Phosphate30$23,992
RybelsusSemaglutide17$20,038
Lantus SolostarInsulin Glargine,hum.Rec.Anlog97$15,938
XareltoRivaroxaban13$14,515
Repatha SureclickEvolocumab13$11,378
Novolog FlexpenInsulin Aspart17$6,487
MyrbetriqMirabegron13$6,321
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$6,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog$37$126,335103 claims
Novo NordiskOzempic, Rybelsus$284$117,709101 claims
GSKTrelegy Ellipta$29$70,77788 claims
AstraZenecaFarxiga$273$52,59553 claims
PfizerEliquis$38$50,30850 claims
Johnson & JohnsonXarelto$20$14,51513 claims
Astellas Pharma US IncMyrbetriq$22$6,32113 claims
AbbVieSynthroid$610$59022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Cambridge City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →